Conclusion The journey to better health often requires more than just one tool
High-throughput and high-sensitivity phosphoproteomics with the EasyPhos platform
In Eli Lillys Phase 3 TRIUMPH-1 trial (NCT05929066), 2,339 adults without diabetes received once-weekly retatrutide at 4 mg, 9 mg, or 12 mg, or placebo, for 80 weeks, with topline results announced in May 2026
Together, we can save lives
We can integrate compounding prescriptions with diet programs, injections, blended formulas of B-complex vitamins and lipotropins that can help metabolize fat
Computational modeling studies reveal the origin of the binding preference of 3-(3,4-di hydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids for AKR1C3 over its isoforms